Spero Therapeutics Announces $105M In Non-Recourse Non-Dilutive Royalty Financing With KKR's Healthcare Royalty
Benzinga Newsdesk 3 months ago
News
Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent BiologicsTransaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and
- Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics
- Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and royalties, and positions Spero to participate in potential long-term commercial upside
- Spero updates its cash runway guidance into the second half of 2029